Howard Doran Jr. - 20 Nov 2023 Form 4 Insider Report for Renalytix plc (RNLXY)

Role
Chief Business Officer
Signature
/s/ Katie Kazem, Attorney-in-Fact
Issuer symbol
RNLXY
Transactions as of
20 Nov 2023
Net transactions value
$0
Form type
4
Filing time
22 Nov 2023, 16:27:24 UTC
Previous filing
12 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNLX Employee Stock Option (right to buy) Award $0 +300,000 $0.000000 300,000 20 Nov 2023 Ordinary Shares 300,000 $0.3040 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
F2 One third (1/3rd) of the shares subject to the option award shall vest on September 1, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.